Cargando…

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis

AIM OF THE STUDY: The Patient Assistance Program, a type of expanded access program, was initiated for compassionate purposes to provide ipilimumab to patients with unresectable stage III or IV melanoma with failed previous treatment. The aim of this analysis is to evaluate efficacy, safety, and tol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiater, Katarzyna, Świtaj, Tomasz, Mackiewicz, Jacek, Kalinka-Warzocha, Ewa, Wojtukiewicz, Marek, Szambora, Paweł, Falkowski, Sławomir, Rogowski, Wojciech, Mackiewicz, Andrzej, Rutkowski, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934064/ https://www.ncbi.nlm.nih.gov/pubmed/24596511 http://dx.doi.org/10.5114/wo.2013.35785

Ejemplares similares

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial
por: Rutkowski, Piotr, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Recent advances in melanoma treatment – American Society of Clinical Oncology (ASCO) 2012 perspective
por: Mackiewicz, Jacek, et al.
Publicado: (2012)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors—A Sarcoma Reference Center Experience
por: Sobczuk, Paweł, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

What is new in the treatment of advanced melanoma? State of the art
por: Mackiewicz, Jacek
Publicado: (2012)

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
por: Pietrzak, Bernadeta, et al.
Publicado: (2022)

The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma
por: Kozak, Katarzyna, et al.
Publicado: (2020)

Is good more alike than bad? Positive-negative asymmetry in the differentiation between options. A study on the evaluation of fictitious political profiles
por: Jablonska, Magdalena, et al.
Publicado: (2022)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023)

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019)

Editorial to the Special Issue on Skin Cancer: The State of the Art
por: Rutkowski, Piotr, et al.
Publicado: (2022)

Analysis of sequence variants in the 3'UTR of CDKN2A gene in melanoma patients
por: Przybyła, Anna, et al.
Publicado: (2015)

The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
por: Sobczuk, Paweł, et al.
Publicado: (2022)

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6
por: Czerwinska, Patrycja, et al.
Publicado: (2020)

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma
por: Jacek, Mackiewicz, et al.
Publicado: (2015)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
por: Rogala, Paweł, et al.
Publicado: (2022)

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
por: Pacholczak-Madej, Renata, et al.
Publicado: (2022)

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines
por: Guglas, Kacper, et al.
Publicado: (2018)

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma—Case Report
por: Czepczyński, Rafał, et al.
Publicado: (2021)

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
por: Przybyla, Anna, et al.
Publicado: (2021)

Age as a Prognostic Factor in Patients with Ewing Sarcoma—The Polish Sarcoma Group Experience
por: Jagodzińska-Mucha, Paulina, et al.
Publicado: (2021)

Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2017)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
por: Tomela, Katarzyna, et al.
Publicado: (2020)

PRINS lncRNA Is a New Biomarker Candidate for HPV Infection and Prognosis of Head and Neck Squamous Cell Carcinomas
por: Kopczyńska, Magda, et al.
Publicado: (2020)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
por: Kwiatkowska-Borowczyk, Eliza, et al.
Publicado: (2018)

The Effect of Spring Barley Fertilization on the Content of Polycyclic Aromatic Hydrocarbons, Microbial Counts and Enzymatic Activity in Soil
por: Mackiewicz-Walec, Ewa, et al.
Publicado: (2023)

Content of polycyclic aromatic hydrocarbons in soil in a multi-annual fertilisation regime
por: Mackiewicz-Walec, Ewa, et al.
Publicado: (2020)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck
por: Łasińska, Izabela, et al.
Publicado: (2020)

Management Strategies for Adults with Locally Advanced, Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa): Challenges and Solutions
por: Czarnecka, Anna M, et al.
Publicado: (2023)

LATS1 Is a Mediator of Melanogenesis in Response to Oxidative Stress and Regulator of Melanoma Growth
por: Kazimierczak, Urszula, et al.
Publicado: (2021)

The origin of the expressed retrotransposed gene ACTBL2 and its influence on human melanoma cells’ motility and focal adhesion formation
por: Malek, Natalia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b4nh3vqa0oe0ulqi2u7o16fuc7